Boston, MA – According to filings with the U.S. Securities and Exchange Commission, IFM Quattro is raising $5,000,002.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Martin Seidel played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About IFM Quattro

At IFM Therapeutics, LLC, we are transforming immunotherapy to improve the lives of patients with serious diseases. We focus on developing small molecule drugs that precisely target the innate immune system, the body’s first line of immunological response. IFM Therapeutics, LLC was formed following the acquisition of IFM Therapeutics by Bristol-Myers Squibb in 2017. IFM Therapeutics, LLC retained its personnel and facilities, as well as its remaining research programs focused on curbing immune responses that lead to inflammatory diseases and fibrosis. By focusing on innate immunity, IFM Therapeutics, LLC is looking to solve the limitations faced by current immunotherapies by dramatically increasing the number of patients that benefit from treatment and extending the duration of therapeutic response.

To learn more about IFM Quattro, visit http://www.ifmthera.com/

Contact:
Martin Seidel, Chief Executive Officer
857-327-9903
https://www.linkedin.com/in/h-martin-seidel-41a18b8/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved